When Multibillion-Dollar Fines Become Just Another Line Item in the Corporate Budget
Between 2010 and 2025, twelve makers of cancer drugs resolved 25 cases with authorities across 10 countries, paying out nearly $1.7 billion in penalties. Yet, according to data from an extensive global review by the International Consortium of Investigative Journalists (ICIJ), those financial settlements represent a meager one-third of 1% of the nearly $696 billion those same firms accrued during the years the deals were made. For pharmaceutical giants managing life-saving therapeutics, regulatory penalties have effectively transformed from legal deterrents into routine operational expenses.
This stark economic reality leaves patients, taxpayers, and healthcare systems worldwide bearing the brunt of corporate overreach. As corporate accountability advocates point out, when the financial upside of manipulating patent systems, blocking generic competition, and inflating drug prices dwarfs the cost of getting caught, lawbreaking simply remains good business.
The Human Cost Behind Blockbuster Revenues and Legal Battles
The human toll of these corporate strategies is starkly visible in communities far removed from the corporate headquarters in Basel or New Jersey. In South Africa’s Mdantsane township, two neighbors turned advocates—Babalwa Malgas and the late Tobeka Daki—spent years fighting for access to Herceptin, a breast cancer medication produced by Roche. By 2016, a year’s supply of the drug cost roughly $36,000, amounting to four times the average South African household income. Daki ultimately passed away from cancer in November 2016, just as legal and public pressure began forcing government probes into excessive pricing.
The pattern extends well beyond South Africa and a single drug. In the United States, retired professor of nutrition Beth Kitchin faced steep out-of-pocket expenses for Jakafi, a leukemia treatment made by Incyte Corp. In 2021, Incyte agreed to pay $12.6 million to resolve U.S. Justice Department allegations that it utilized kickbacks through charitable foundations to boost prescriptions by covering patient copays. Kitchin noted that she remained entirely unaware of the company’s legal entanglements while struggling to afford the medication. Investigations by Good Jobs First reveal that 11 of these major drugmakers accumulated $15.4 billion in total healthcare fines and settlements between 2010 and 2025, contrasting sharply with the $491 billion in revenues they posted in their latest single fiscal year alone.
Anatomy of Repeat Offenses Across the Global Pharmaceutical Sector
The ICIJ review of criminal and civil cases across 31 countries highlights a persistent cycle of alleged misconduct, including deceptive marketing, kickback schemes, and aggressive patent manipulation designed to delay cheaper biosimilars and generics. Roche, Novartis, and Celgene—now controlled by Bristol Myers Squibb—feature prominently in repeat enforcement actions. Novartis agreed to pay more than $51 million to the U.S. Justice Department in 2020 over kickback allegations tied to the kidney cancer drug Afinitor, marking the third time the company pledged corporate compliance reforms. Meanwhile, Celgene settled for $280 million in 2017 regarding the promotion of Revlimid and Thalomid for multiple myeloma and a range of other cancers beyond the uses then approved by the Food and Drug Administration.
Industry watchdogs emphasize that enforcement agencies rarely hold individual corporate officers personally accountable, nor do they routinely bar repeat corporate offenders from government business. Reuben Guttman, an attorney representing the whistleblower in the Celgene case, summarized the dynamic bluntly, noting that these corporations essentially treat penalties as a fee purchased for a license to break the law. Compounding the issue, whistleblower actions under mechanisms like the False Claims Act drive many of these investigations, yet the resulting settlements routinely fail to establish systemic deterrence across an industry where blockbuster drugs generate billions in annual sales independently of regulatory interventions.
The Path Forward: Rethinking Accountability in Global Healthcare
As global cancer rates climb and lawmakers scrutinize dense webs of overlapping drug patents—such as the ones protecting Merck’s blockbuster immunotherapy Keytruda—the debate over pharmaceutical accountability intensifies.
For cancer survivors like Malgas, who continues her personal health battles while awaiting rulings on pricing conduct, the systemic questions remain urgent. When regulatory penalties are easily absorbed as the cost of doing business, the fundamental question for global healthcare regulators is simple: How can public health systems protect patients when the financial architecture rewards corporate rule-breaking?
